Search results
Results from the WOW.Com Content Network
Here is the list in order of FDA approval date. Read On The Fox News App. 1. Dupixent – Additional use: Eosinophilic esophagitis (an allergic condition that causes inflammation of the esophagus) 2.
The combination drug was approved for medical use in the United States in February 2017, where it also is sold under the brand name Qtern. [ 61 ] [ 62 ] In May 2019, the fixed-dose combination of dapagliflozin, saxagliptin, and metformin hydrochloride as extended-release tablets was approved in the United States to improve glycemic control in ...
Recently, two pharmaceutical giants received FDA approval for a new treatment for type 2 diabetes. Farxiga (dapagliflozin) is a "sodium-glucose co-transporter 2 inhibitor", or SGLT2 inhibitor for ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
For premium support please call: 800-290-4726 more ways to reach us
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
AstraZeneca's blockbuster diabetes drug Farxiga led to significant reductions in the risk of hospitalisation and death in people with all types of heart failure, according to study data released ...
AstraZeneca's SGLT-2 inhibitor dapaglifozin has had a difficult path to market, but the company finally got the FDA's go-ahead to market the drug on Wednesday. While SGLT-2 inhibitors are a promising